AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Dynein regulatory complex subunit 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O95995

UPID:

DRC4_HUMAN

Alternative names:

Growth arrest-specific protein 11; Growth arrest-specific protein 8

Alternative UPACC:

O95995; B2RCT1; B7Z4U1; G3V1L5; Q2M234

Background:

Dynein regulatory complex subunit 4, also known as Growth arrest-specific protein 11, plays a pivotal role in ciliary and flagellar motility. It is a component of the nexin-dynein regulatory complex (N-DRC), crucial for maintaining the alignment and integrity of the distal axoneme. This protein is essential for proper functioning of motile cilia, coordinating their movement, and is involved in hedgehog signaling through regulation of smoothened (SMO) activity.

Therapeutic significance:

Given its critical role in motile cilia functioning and hedgehog signaling, Dynein regulatory complex subunit 4 is linked to Ciliary dyskinesia, primary, 33, a disorder characterized by respiratory infections and chronic inflammation due to ciliary defects. Understanding the role of this protein could open doors to potential therapeutic strategies for treating ciliary dyskinesia.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.